241 related articles for article (PubMed ID: 29483406)
1. [New Opioid Options in Japan - Methadone, Tapentadol and Hydromorphone].
Takagi Y; Aruga E
Gan To Kagaku Ryoho; 2018 Feb; 45(2):205-211. PubMed ID: 29483406
[TBL] [Abstract][Full Text] [Related]
2. Opioids for cancer pain - an overview of Cochrane reviews.
Wiffen PJ; Wee B; Derry S; Bell RF; Moore RA
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012592. PubMed ID: 28683172
[TBL] [Abstract][Full Text] [Related]
3. Tapentadol in Cancer Patients with Neuropathic Pain: A Comparison of Methadone, Oxycodone, Fentanyl, and Hydromorphone.
Takemura M; Niki K; Okamoto Y; Matsuda Y; Omae T; Takagi T; Ueda M
Biol Pharm Bull; 2021; 44(9):1286-1293. PubMed ID: 34471056
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Effects of OPRM1 A118G Polymorphism Using Different Opioids: A Prospective Study.
Takemura M; Niki K; Okamoto Y; Kawamura T; Kohno M; Matsuda Y; Ikeda K
J Pain Symptom Manage; 2024 Jan; 67(1):39-49.e5. PubMed ID: 37757956
[TBL] [Abstract][Full Text] [Related]
5. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
[TBL] [Abstract][Full Text] [Related]
6. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
7. [Opioids for Cancer Pain and its Use under Particular Conditions: A Narrative Review].
Vieira C; Brás M; Fragoso M
Acta Med Port; 2019 May; 32(5):388-399. PubMed ID: 31166900
[TBL] [Abstract][Full Text] [Related]
8. Is tapentadol an advance on tramadol?
Guay DR
Consult Pharm; 2009 Nov; 24(11):833-40. PubMed ID: 20092221
[TBL] [Abstract][Full Text] [Related]
9. Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment.
Butler SF; McNaughton EC; Black RA
Pain Med; 2015 Jan; 16(1):119-30. PubMed ID: 25243972
[TBL] [Abstract][Full Text] [Related]
10. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine.
Bruera E; Pereira J; Watanabe S; Belzile M; Kuehn N; Hanson J
Cancer; 1996 Aug; 78(4):852-7. PubMed ID: 8756381
[TBL] [Abstract][Full Text] [Related]
11. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor.
Hartrick CT; Rozek RJ
CNS Drugs; 2011 May; 25(5):359-70. PubMed ID: 21476608
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
[TBL] [Abstract][Full Text] [Related]
13. Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users.
Stoops WW; Glaser PE; Rush CR
Psychopharmacology (Berl); 2013 Jul; 228(2):255-62. PubMed ID: 23430163
[TBL] [Abstract][Full Text] [Related]
14. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I
Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647
[TBL] [Abstract][Full Text] [Related]
15. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations.
Manfredi PL; Borsook D; Chandler SW; Payne R
Pain; 1997 Mar; 70(1):99-101. PubMed ID: 9106815
[TBL] [Abstract][Full Text] [Related]
16. Tapentadol is effective in the management of moderate-to-severe cancer-related pain in opioid-naïve and opioid-tolerant patients: a retrospective study.
Sazuka S; Koitabashi T
J Anesth; 2020 Dec; 34(6):834-840. PubMed ID: 32648017
[TBL] [Abstract][Full Text] [Related]
17. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences.
Ripamonti C; De Conno F; Groff L; Belzile M; Pereira J; Hanson J; Bruera E
Ann Oncol; 1998 Jan; 9(1):79-83. PubMed ID: 9541687
[TBL] [Abstract][Full Text] [Related]
18. Unique pharmacology of tapentadol for treating acute and chronic pain.
Knezevic NN; Tverdohleb T; Knezevic I; Candido KD
Expert Opin Drug Metab Toxicol; 2015; 11(9):1475-92. PubMed ID: 26215077
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of tapentadol for first-line opioid-resistant neuropathic pain in Japan.
Sugiyama Y; Kataoka T; Tasaki Y; Kondo Y; Sato N; Naiki T; Sakamoto N; Akechi T; Kimura K
Jpn J Clin Oncol; 2018 Apr; 48(4):362-366. PubMed ID: 29506199
[TBL] [Abstract][Full Text] [Related]
20. Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids.
Mercadante S; Porzio G; Aielli F; Adile C; Verna L; Ficorella C; Giarratano A; Casuccio A
Curr Med Res Opin; 2013 Jun; 29(6):661-6. PubMed ID: 23540512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
